Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study
| Autor: | Ghada Bawazeer, Ward Alessa, Lamya Alnaim, Nora Al-Orf, Hadeel Alkofide |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
anthracyclines
medicine.medical_specialty Cardiotoxicity education.field_of_study cardiac monitoring Anthracycline business.industry medicine.medical_treatment education Population anthracyclines-induced cardiotoxicity Retrospective cohort study Guideline Odds ratio Institutional review board Oncology Cancer Management and Research Internal medicine medicine cancer Cardiac monitoring business Original Research |
| Zdroj: | Cancer Management and Research |
| ISSN: | 1179-1322 |
| Popis: | Hadeel Alkofide,1 Lamya Alnaim,1 Nora Alorf,2 Ward Alessa,2 Ghada Bawazeer1 1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; 2College of Pharmacy, King Saud University, Riyadh, Saudi ArabiaCorrespondence: Hadeel AlkofideDepartment of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, 11149, Saudi ArabiaTel +966503225121Email halkofide@ksu.edu.saPurpose: Cardiotoxicity is a common complication associated with anthracyclines. Little is known regarding the rate of anthracyclines-related acute and chronic cardiotoxicity and adherence to cardiac monitoring recommendations among cancer patients.Patients and Methods: A single-centre retrospective cohort study was conducted from 2015 to 2018 on patients with cancer, 18 years of age and older, on anthracyclines without a history of cardiovascular diseases. Data on demographic information, comorbidities, cardiovascular events, monitoring parameters, and treatment details were obtained. The primary outcome was the incidence of anthracyclines-related cardiotoxicity both acute and chronic. The secondary outcome was to determine adherence to guideline recommendations for monitoring anthracyclines-related cardiotoxicity based on the American Society of Clinical Oncology clinical practice guidelines. Analyses included descriptive statistics and logistic regression. Institutional review board approval was obtained.Results: In 235 patients identified, 28.9% developed cardiotoxicity, of which 27.2% were acute, while chronic cardiotoxicity was observed in 8.9% of subjects. Patients who received optimal cardiac monitoring had a statistically significant higher odds of developing cardiotoxicities (odds ratio=2.65, confidence interval=1.32â 5.33). The risk of cardiotoxicity was higher in subjects with a history of diabetes mellitus, those using daunorubicin, and concomitant filgrastim use. Adherence to guideline recommendations was only achieved in 25.1% of the population. Echocardiography was the most common monitoring method used.Conclusion: In this study, there was a high incidence of anthracyclines cardiotoxicity and poor compliance with cardiac monitoring recommendations for cancer patients on anthracyclines, which underscores acute and chronic cardiotoxicity in this population.Keywords: anthracyclines, anthracyclines-induced cardiotoxicity, cardiac monitoring, cancer |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|